TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17225706
Drug: Leukotriene inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene inhibitors
Study: 21818628
Drug: Galantamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine treatment
Study: 19884223
Drug: Therapist-led group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-led group treatment
Study: 18299490
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both traditional decision aid and chronic disease trajectory model
Study: 17312857
Drug: Polypeptide-based heparin-bonded
Normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypeptide-based heparin-bonded circuits with reduced heparinization
Study: 22817699
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol
Study: 30950894
Drug: Cyclotorsion compensated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclotorsion compensated SMILE surgery (CC group: 54 eyes)
Study: 28385705
Drug: 3-year specialised
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-year specialised treatment (extended early intervention)
Study: 25823909
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml 0.5% silver nitrate
Study: 25823909
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml 0.3% silver nitrate
Study: 23097311
Drug: SC abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SC abatacept (125 mg/week) with methotrexate (combination)
Study: 23097311
Drug: Long-term extension
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term extension (LTE) with SC abatacept without methotrexate (monotherapy)
Study: 16484573
Drug: High-dose AGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AGE (2.4 mL/d)
Study: 16484573
Drug: Low-dose AGE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AGE (0.16 mL/d)
Study: 7722710
Drug: Atole (high-energy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atole (high-energy, high-protein supplement: 163 kcal/682 kJ and 6.4 g protein per serving)
Study: 7722710
Drug: Fresco (low-energy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresco (low-energy, no-protein supplement: 59 kcal/247 kJ per 180 mL)
Study: 2126727
Drug: Active nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nitroglycerin patches (10mg/24hrs)
Study: 7237200
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg orally two hours pre-operatively
Study: 7237200
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 0.3 M solution 30 ml orally
Study: 7659199
Drug: Electroconvulsive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive treatment (ECT)
Study: 23702050
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (8 weekly sessions of 90 minutes each)
Study: 23702050
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) (8 weekly sessions of 90 minutes each)
Study: 20425129
Drug: Intravenous cannula
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cannula stillete (IVCS)
Study: 19536452
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg twice daily) and omeprazole (20 mg once daily) for 18 months
Study: 11433128
Drug: Lisinopril 5mg
Normalized name: LISINOPRIL 5MG TAB
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril 5mg (low dose)
Study: 9622936
Drug: Low Molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparins (LMWH) at home followed by oral anticoagulant
Study: 9622936
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) in hospital followed by oral anticoagulant
Study: 9773138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without lidocaine infusion
Study: 2626338
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine mouthrinse, 15 ml, 3 times daily
Study: 1107960
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ten units of regular insulin twice a day for five days
Study: 26431124
Drug: Intraarticular facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular facet joint injections
Study: 17110816
Drug: Intravenous glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glycine infusion
Study: 11302905
Drug: Acid suppressing
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid suppressing drugs or specialist referral at general practitioner's discretion
Study: 23765630
Drug: Netupitant 50
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant 50 mg
Study: 30576544
Drug: Netupitant 100
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant 100 mg
Study: 23765630
Drug: Netupitant 200
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant 200 mg
Study: 15118196
Drug: CordyMax Cs-4
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CordyMax Cs-4 (3 g/d)
Study: 16700802
Drug: Eberconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eberconazole 1% cream
Study: 9571333
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (insulin therapy alone)
Study: 29389170
Drug: Varenicline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 2 mg/day
Study: 11165950
Drug: Risedronate 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 20 mg/day for 14 days, followed by placebo for 42 days
Study: 11165950
Drug: Risedronate 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 20 mg/day for 14 days, followed by elemental calcium 1000 mg/day and placebo for 14 days, then by placebo for 28 days
Study: 11165950
Drug: Risedronate 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 20 mg/day for 7 days, followed by elemental calcium 1000 mg/day and placebo for 21 days, then risedronate 20 mg/day for 7 days, and finally elemental calcium 1000 mg/day and placebo for 21 days
Study: 2742099
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) administered intravenously 8 minutes before induction
Study: 26618458
Drug: 3 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times injection with 4 cc dose
Study: 22995453
Drug: No antifibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifibrinolytic agent or placebo (Control Group).
Study: 17178496
Drug: Podophyllin resin
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllin resin (25%) together with acyclovir cream (5%)
Study: 7512659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PSA and digital rectal examination
Study: 18562773
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) supplementation (1 g/kg body weight)
Study: 15799734
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% solution subconjunctivally
Study: 15799734
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% gel topically
Study: 1897347
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 4 ml.h‐1 (BUPI‐group)
Study: 1897347
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine bolus followed by 0.2 mg.h‐1 (MO‐group)
Study: 1897347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine and morphine (COMB-group)
Study: 30239650
Drug: Cenicriviroc (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (100 mg dose)
Study: 27046162
Drug: Ticagrelor (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (pooled doses)
Study: 23030511
Drug: Long-pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulsed Nd:YAG laser (LPNY) treatment
Study: 10404908
Drug: Zanamivir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (10 mg once daily for 4 weeks)
Study: 7758492
Drug: Gentamicin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4.5 mg/kg once daily
Study: 7758492
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg every eight hours (thrice daily)
Study: 24119112
Drug: TY 8
Normalized name: Maxclarity 8 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY 8 mg (bisoprolol transdermal patch)
Study: 24119112
Drug: BO 5
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: BO 5 mg (bisoprolol fumarate oral formulation)
Study: 12359793
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/d for 2 days, then 0.25 mg/kg/d for 2 days)
Study: 9695133
Drug: Lupron injections
Normalized name: Lupron Injectable Product
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron injections (GnRH agonist) followed by resuming menstrual cycles (Cycle)
Study: 2475059
Drug: four different
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: four different oral refeeding regimes
Study: 23336668
Drug: Glimepiride/metformin (GM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride/metformin (GM) 1/250 mg twice daily
Study: 23336668
Drug: Glimepiride/metformin sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride/metformin sustained release (GM-SR) 2/500 mg once daily
Study: 15073257
Drug: (188)Re-HDD/lipiodol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (188)Re-HDD/lipiodol therapy
Study: 15073257
Drug: (131)I-lipiodol therapy
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I-lipiodol therapy
Study: 15078725
Drug: Dobutamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (10 micro g/kg/min for 8 h every 14 days) + oral amiodarone (400 mg/d)
Study: 15078725
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + oral amiodarone (400 mg/d)
Study: 11427359
Drug: Uncoated placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated placebo tablet (round)
Study: 11427359
Drug: Film-coated placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated placebo risedronate tablet (oval)
Study: 2700320
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg twice daily for 15 days, then 40 mg twice daily for 45 days
Study: 2700320
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once daily for 60 days
Study: 765382
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (100 mug 4 times daily)
Study: 27721190
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation for depression via same-room treatment
Study: 26125257
Drug: Infrared polarized
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared polarized light therapy (group B)
Study: 26125257
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin treatment (group C)
Study: 26125257
Drug: Joint treatment
Normalized name: ARNICA MONTANA FLOWER 2 g in 20 g / APIS MELLIFERA VENOM 6 g in 20 g TOPICAL CREAM [HOUKEA Venom Flex Joint Treatment Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint treatment (group D)
Study: 7948439
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what treatment)
Study: 7884789
Drug: Enalapril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (12.5 +/- 6.5 mg/day)
Study: 2905254
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 75 mg daily
Study: 2905254
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 150 mg daily
Study: 31472811
Drug: Evidence-based multifaceted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based multifaceted intervention including automated identification of patients at increased risk for CI-AKI, point-of-care information on safe contrast volume targets, personalized recommendations for hemodynamic optimization of intravenous fluids, and follow-up information for patients at risk.
Study: 23449352
Drug: Sequential transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential transarterial chemoembolisation (sTACE) with cisplatin 50 mg administered intrarterially 4‐6 hours before PVA embolisation, repeated 3-weekly for up to three treatments
Study: 23449352
Drug: Transarterial embolisation
Normalized name: Drugs for embolisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial embolisation (TAE) with polyvinyl alcohol (PVA) particles alone, repeated 3-weekly for up to three treatments
Study: 19372355
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine perineural infusion (n = 15)
Study: 19372355
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (n = 15)
Study: 19372355
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine perineural infusion
Study: 15131791
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, 40,000 U subcutaneously, once weekly
Study: 15374309
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (informal monthly meetings of the Alzheimer's Society)
Study: 2646896
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hydrochlorothiazide (HCTZ), 25 mg twice daily, with dose reduction
Study: 2646896
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hydrochlorothiazide (HCTZ), 50 mg twice daily, with dose reduction
Study: 2646896
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose HCTZ plus a low or high dose of a step II drug (propranolol, clonidine or reserpine), with dose reduction
Study: 2646896
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving continued treatment
Study: 30545702
Drug: Standard post-operative
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-operative analgesia (paracetamol and dexketoprofen)
Study: 27435514
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (250 mg bolus followed by 500 mg infusion at 20 mL/hour)
Study: 11880827
Drug: Piroxicam fast-dissolving
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Piroxicam fast-dissolving dosage form (2 tablets sublingually 1 to 3 hours before surgery, repeated with 2 tablets after 24 hours, then 1 tablet after 48 hours)
Study: 11880827
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets administered sublingually 1 to 3 hours before surgery, repeated with 2 tablets after 24 hours, then 1 tablet after 48 hours)
Study: 7589042
Drug: i.v. 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 0.2 mg moxonidine
Study: 23815518
Drug: Natural cholesterol‐lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural cholesterol‐lowering supplement (NCLS)
Study: 19626475
Drug: Gadobutrol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobutrol (0.1 ml/kg)
Study: 17908831
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) administered 1 hour before blood collection
Study: 15520759
Drug: Probiotic lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lactobacilli (Lactobacillus rhamnosus 19070‐2 and L reuteri DSM 12246) for 6 weeks
Study: 15520759
Drug: Probiotic lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lactobacilli (Lactobacillus rhamnosus 19070‐2 and L reuteri DSM 12246)
Study: 7839785
Drug: Clonidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3 micrograms.kg‐1 mixed with 15 mg 0.5% bupivacaine
Study: 7839785
Drug: Saline mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline mixed with 15 mg 0.5% bupivacaine
Study: 24731441
Drug: mCBT (guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCBT (guided Internet-based cognitive behavior therapy)
Study: 24731441
Drug: mIPT (guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: mIPT (guided self-help treatment based on interpersonal psychotherapy)
Study: 10697029
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 plus carboplatin (AUC = 6)
Study: 8222793
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (200 mg, bid)
Study: 8473547
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg once daily
Study: 31609709
Drug: Antibiotic and
Normalized name: Triple Antibiotic And Pain Relief
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic and antimycotic impregnated PICC (IP-PICC)
Study: 16158748
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative etiotropic therapy
Study: 7735445
Drug: Amoxicillin-clavulanate
Normalized name: amoxicillin-clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate
Study: 15293527
Drug: Enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-20 mg/day)
Study: 2540054
Drug: Nicardipine (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60-120 mg/day)
Study: 30192802
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment during stimulation with IFNγ and TNFα
Study: 30192802
Drug: Chemical inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical inhibition of EGFR signaling (using MEK1/2 inhibitor PD98059 and JNK inhibitor SP600125)
Study: 30192802
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with cetuximab and MEK1/2 or JNK inhibitor
Study: 27342447
Drug: Ketamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (100 ng/mL target plasma concentration)
Study: 8030656
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous saline)
Study: 20398482
Drug: Benidipine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (8 mg/d)
Study: 9848776
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg/d)
Study: 9764629
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT
Study: 9764629
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT
Study: 9211571
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg daily
Study: 3284322
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 or 80 mg 3 times daily)
Study: 1095307
Drug: Bromhexine, 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine, 16 mg, 3-times daily for 3 weeks
Study: 25887128
Drug: Cuticerin™ (smooth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuticerin™ (smooth acetate gauze with water-repellent ointment)
Study: 19214143
Drug: Montelukast (cys-leukotriene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (cys-leukotriene receptor antagonist)
Study: 21867401
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA)
Study: 16390353
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg once daily for 6 days
Study: 30691748
Drug: Traditional Dysphagia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Dysphagia Therapy (TDT) - sensorimotor exercises and swallowing maneuvers
Study: 30691748
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC) - diet prescription and postural changes
Study: 28834296
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (group B)